Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies
暂无分享,去创建一个
A. Stamatoullas | B. Quesnel | P. Fenaux | J. Delaunay | O. Beyne-Rauzy | F. Dreyfus | E. Raffoux | C. Berthou | T. Prebet | B. Choufi | S. Bréchignac | A. Taksin | Y. Hicheri | M. Hacini | C. Kelaidi | A. Guerci | L. Legros | H. Zerazhi | M. Gourin | J. Camo
[1] U. Germing,et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes , 2009, European journal of haematology.
[2] U. Germing,et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). , 2009, Leukemia research.
[3] H. Kantarjian,et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. , 2008, Journal of the National Cancer Institute.
[4] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Dombret,et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.
[6] N. Howlader,et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.
[7] N. Gattermann. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload , 2008, International journal of hematology.
[8] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[9] M. Somerfield,et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Somerfield,et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. , 2008, Blood.
[11] G. Ehninger,et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation. , 2007, Blood.
[12] B. Johansson,et al. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. , 2007, Pathologie-biologie.
[13] U. Germing,et al. Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Mufti,et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. , 2006, Blood.
[15] L. Mannone,et al. High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.
[16] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[17] F. Mandelli,et al. Myelodysplastic syndromes in patients under 50 years old: a single institution experience. , 2005, Leukemia research.
[18] I. Dybedal,et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.
[19] D. Arber,et al. Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients , 2002, Leukemia.
[20] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[21] C. Preudhomme,et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France , 2001, British journal of haematology.
[22] U. Germing,et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.
[23] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[24] E. Wattel,et al. Low incidence of specific anti‐platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy , 1996, British journal of haematology.
[25] D. A. Stafford,et al. Occupational and environmental exposures and myelodysplasia: a case-control study. , 1995, Leukemia research.
[26] D. Oscier,et al. Establishing the incidence of myelodysplastic syndrome. , 1994, British journal of haematology.
[27] E. Wattel,et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases , 1994, British journal of haematology.
[28] N. Gattermann,et al. Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.
[29] C. Preudhomme,et al. de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. , 1990, Leukemia research.
[30] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.